



IFW 1644\$


PATENT  
Attorney Docket No. MEE-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Miller *et al.*  
SERIAL NO.: 09/780,142 GROUP NO.: 1644  
FILING DATE: February 9, 2001 EXAMINER: Huynh, P.  
TITLE: METHODS AND COMPOSITIONS FOR TREATING CONDITIONS  
OF THE EYE

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 24<sup>th</sup> day of March, 2005.

  
Carrah M. Malone


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is/are:

1. Transmittal Form (1 page);
2. Fee Transmittal (1 page);
3. Check in the amount of \$180.00;
4. Supplemental Information Disclosure Statement (2 pages),
5. Form PTO 1449 (4 pages);
6. Copies of cited references B8-B11 and C119-C169; and
7. Return Receipt Postcard

VER 9/00



# TRANSMITTAL FORM

|                           |                  |
|---------------------------|------------------|
| Application Serial Number | 09/780,142       |
| Filing Date               | February 9, 2001 |
| First Named Inventor      | Miller           |
| Group Art Unit            | 1644             |
| Examiner Name             | Huynh, P.        |
| Attorney Docket No.       | MEE-002          |
| Patent No.                | Not applicable   |
| Issue Date                | Not applicable   |


## ENCLOSURES (check all that apply)

|   |   |   |
|---|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input checked="" type="checkbox"/> Check Attached<br><input type="checkbox"/> Copy of Fee Transmittal Form<br><input type="checkbox"/> Amendment/Response<br><input type="checkbox"/> Preliminary<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]<br><input type="checkbox"/> Petition for Extension of Time<br><input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pgs.)<br><input checked="" type="checkbox"/> Form PTO-1449<br><input checked="" type="checkbox"/> Copies of IDS Citations (B8-B11 and C119-C169)<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Sequence Listing submission<br><input type="checkbox"/> Paper Copy/CD<br><input type="checkbox"/> Computer Readable Copy<br><input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application<br><input type="checkbox"/> Formal Drawing(s)<br><input type="checkbox"/> Request For Continued Examination (RCE) Transmittal<br><input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application<br><input type="checkbox"/> Small Entity Statement<br><input type="checkbox"/> CD(s) for large table or computer program<br><input type="checkbox"/> Amendment After Allowance<br><input type="checkbox"/> Request for Certificate of Correction<br><input type="checkbox"/> Certificate of Correction (in duplicate) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences<br><input type="checkbox"/> Appeal Brief (in triplicate)<br><input type="checkbox"/> Status Inquiry<br><input checked="" type="checkbox"/> Return Receipt Postcard<br><input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8<br><input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8<br><input type="checkbox"/> Additional Enclosure(s) (please identify below) |
|---|---|---|


## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
Goodwin Procter LLP  
Exchange Place  
Boston, MA 02109  
Tel. No.: (617) 570-1000  
Fax No.: (617) 523-1231  
Customer No. 051414


## SIGNATURE BLOCK

Respectfully submitted,  
  
Duncan A. Greenhalgh  
Attorney for Applicants  
Goodwin Procter LLP  
Exchange Place  
Boston, MA 02109

Date: March 24, 2005  
Reg. No. 38,678  
Tel. No.: (617) 570-1299  
Fax No.: (617) 523-1231

|   |                           |                  |
|---|---------------------------|------------------|
|  | Complete if Known         |                  |
|   | Application Serial Number | 09/780,142       |
|   | Filing Date               | February 9, 2001 |
|   | First Named Inventor      | Miller           |
|   | Group Art Unit            | 1644             |
|   | Examiner Name             | Huynh, P.        |
|   | Attorney Docket No.       | MEE-002          |

| METHOD OF PAYMENT  | FEE CALCULATION (continued)   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
|--|---|--|-----------------------|-----------------|--------------------|-----|-----|-------------------------------------|--|-----|------------------|--|-----|--|-----|---------------------------|-------------------|-------|-------|------------------------------------|--|-----|-----------------|--|-----|---|-----|---|--------------|------|--------|--|--------|--------------|-----|---|-------|--------------|------|--|--|-----|------------|------------------|--|-----|-----|--|--|------|-----|--------------------------|--|-----|-----------|---------------------------------------|---------------------------------|---------------|------|--|-------|-----|-----|---|--|--------|-----|--|--------------|-----|-----|---|--|--------------|-----|--|--|-----|-----|---|------------------------|-----|----|-----------------------------------|------|---------------------------|--|--|--|---------------------------|--|--|--|--------------|--------------------|
| 1. <input checked="" type="checkbox"/> Payment Enclosed:<br><input checked="" type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other<br><br>2. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 07-1700.<br><input type="checkbox"/> Required Fees (copy of this sheet enclosed).<br><input checked="" type="checkbox"/> Additional fee required under 37 CFR 1.16 and 1.17.<br><input checked="" type="checkbox"/> Overpayment Credit.<br>3. <input checked="" type="checkbox"/> Applicant claims small entity status.   | <div style="border-bottom: 1px solid black; padding-bottom: 5px;"> <b>3. ADDITIONAL FEES</b> </div> <table style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">Large Entity Fee (\$)</th> <th style="width:15%;">Small Entity Fee (\$)</th> <th style="width:55%;">Fee Description</th> <th style="width:15%;">Fee Paid</th> </tr> </thead> <tbody> <tr><td>130</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>50</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>130</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>2,520</td><td>2,520</td><td>Request for ex parte reexamination</td><td></td></tr> <tr><td>120</td><td>60</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>450</td><td>225</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>1020</td><td>510</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>1590</td><td>795</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>2160</td><td>1080</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>500</td><td>250</td><td>Notice of Appeal</td><td></td></tr> <tr><td>500</td><td>250</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>1000</td><td>500</td><td>Request for oral hearing</td><td></td></tr> <tr><td>400</td><td>400</td><td>Petitions to the Commissioner (Gp. I)</td><td></td></tr> <tr><td>200</td><td>200</td><td>Petitions to the Commissioner (Gp. II)</td><td></td></tr> <tr><td>130</td><td>130</td><td>Petitions to the Commissioner (Gp. III)</td><td></td></tr> <tr><td>180</td><td>180</td><td>Submission of Information Disclosure Statement</td><td>180.00</td></tr> <tr><td>790</td><td>395</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>790</td><td>395</td><td>For each additional invention to be examined (37 CFR 1.129(b))</td><td></td></tr> <tr><td>100</td><td>100</td><td>Certificate of Correction for applicant's error</td><td></td></tr> <tr><td>130</td><td>65</td><td>Submission of Terminal Disclaimer</td><td></td></tr> <tr><td colspan="2">Other fee (Specify) _____</td><td></td><td></td></tr> <tr><td colspan="2">Other fee (Specify) _____</td><td></td><td></td></tr> </tbody> </table> <div style="text-align: right; border-top: 1px solid black; padding-top: 5px;"> <b>SUBTOTAL (3)</b>      (\$)      180.00         </div> | Large Entity Fee (\$)  | Small Entity Fee (\$) | Fee Description | Fee Paid           | 130 | 65  | Surcharge - late filing fee or oath |  | 50  | 25               | Surcharge - late provisional filing fee or cover sheet |     | 130  | 130 | Non-English specification |                   | 2,520 | 2,520 | Request for ex parte reexamination |  | 120 | 60              | Extension for reply within first month |     | 450   | 225 | Extension for reply within second month |              | 1020 | 510    | Extension for reply within third month |        | 1590         | 795 | Extension for reply within fourth month |       | 2160         | 1080 | Extension for reply within fifth month |  | 500 | 250        | Notice of Appeal |  | 500 | 250 | Filing a brief in support of an appeal |  | 1000 | 500 | Request for oral hearing |  | 400 | 400       | Petitions to the Commissioner (Gp. I) |                                 | 200           | 200  | Petitions to the Commissioner (Gp. II) |       | 130 | 130 | Petitions to the Commissioner (Gp. III) |  | 180    | 180 | Submission of Information Disclosure Statement | 180.00       | 790 | 395 | Filing a submission after final rejection (37 CFR 1.129(a)) |  | 790          | 395 | For each additional invention to be examined (37 CFR 1.129(b)) |  | 100 | 100 | Certificate of Correction for applicant's error |                        | 130 | 65 | Submission of Terminal Disclaimer |      | Other fee (Specify) _____ |  |  |  | Other fee (Specify) _____ |  |  |  |              |                    |
| Large Entity Fee (\$)  | Small Entity Fee (\$)   | Fee Description  | Fee Paid              |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 130  | 65  | Surcharge - late filing fee or oath                            |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 50   | 25  | Surcharge - late provisional filing fee or cover sheet         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 130  | 130   | Non-English specification                                      |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 2,520  | 2,520   | Request for ex parte reexamination                             |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 120  | 60  | Extension for reply within first month                         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 450  | 225   | Extension for reply within second month                        |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 1020   | 510   | Extension for reply within third month                         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 1590   | 795   | Extension for reply within fourth month                        |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 2160   | 1080  | Extension for reply within fifth month                         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 500  | 250   | Notice of Appeal   |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 500  | 250   | Filing a brief in support of an appeal                         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 1000   | 500   | Request for oral hearing                                       |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 400  | 400   | Petitions to the Commissioner (Gp. I)                          |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 200  | 200   | Petitions to the Commissioner (Gp. II)                         |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 130  | 130   | Petitions to the Commissioner (Gp. III)                        |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 180  | 180   | Submission of Information Disclosure Statement                 | 180.00                |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 790  | 395   | Filing a submission after final rejection (37 CFR 1.129(a))    |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 790  | 395   | For each additional invention to be examined (37 CFR 1.129(b)) |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 100  | 100   | Certificate of Correction for applicant's error                |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 130  | 65  | Submission of Terminal Disclaimer                              |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Other fee (Specify) _____  |   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Other fee (Specify) _____  |   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| <div style="border-bottom: 1px solid black; padding-bottom: 5px;"> <b>1. FILING/SEARCH/EXAM/SIZE FEES</b> </div> <table style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">Large Entity Fee (\$)</th> <th style="width:55%;">Fee Description</th> <th style="width:30%;">Fee Paid</th> </tr> </thead> <tbody> <tr><td>300</td><td>Utility filing fee</td><td></td></tr> <tr><td>500</td><td>Utility search fee</td><td></td></tr> <tr><td>200</td><td>Utility exam fee</td><td></td></tr> <tr><td>250</td><td>Utility size fee (each add'l 50 pgs. over 100)</td><td></td></tr> <tr><td>200</td><td>Design filing fee</td><td></td></tr> <tr><td>100</td><td>Design search fee</td><td></td></tr> <tr><td>130</td><td>Design exam fee</td><td></td></tr> <tr><td>250</td><td>Design size fee (each add'l 50 pgs. over 100)</td><td></td></tr> </tbody> </table><br><table style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:15%;">Amount</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>- 20 =</td> <td>x \$ 50.00 =</td> <td></td> </tr> <tr> <td>Independent Claims</td> <td>- 3 =</td> <td>x \$200.00 =</td> <td></td> </tr> <tr> <td colspan="3"></td> <td>\$360.00 =</td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL:</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (1)</td> <td>(\$) 0.00</td> </tr> </tbody> </table> <div style="border-bottom: 1px solid black; padding-bottom: 5px;"> <b>2. AMENDMENT CLAIM FEES</b> </div> <table style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">Claims Remaining After Amend.</th> <th style="width:15%;">Highest No. Previously Paid For</th> <th style="width:15%;">Present Extra</th> <th style="width:15%;">Rate</th> <th style="width:15%;">Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Total</td> <td>-</td> <td>=</td> <td>x \$ 50.00 =</td> <td></td> </tr> <tr> <td>Indep.</td> <td>-</td> <td>=</td> <td>x \$200.00 =</td> <td></td> </tr> <tr> <td colspan="3"></td> <td>+ \$360.00 =</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL:</td> <td>(\$)</td> </tr> <tr> <td colspan="4" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td>(\$)</td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL (2)</td> <td>(\$) 0.00</td> </tr> </tbody> </table> | Large Entity Fee (\$)   | Fee Description  | Fee Paid              | 300             | Utility filing fee |     | 500 | Utility search fee                  |  | 200 | Utility exam fee |  | 250 | Utility size fee (each add'l 50 pgs. over 100) |     | 200                       | Design filing fee |       | 100   | Design search fee                  |  | 130 | Design exam fee |  | 250 | Design size fee (each add'l 50 pgs. over 100) |     | Number Filed                            | Number Extra | Rate | Amount | Total Claims                           | - 20 = | x \$ 50.00 = |     | Independent Claims                      | - 3 = | x \$200.00 = |      |  |  |     | \$360.00 = | TOTAL:           |  |     |     | SMALL ENTITY DISCOUNT:                 |  |      |     | SUBTOTAL (1)             |  |     | (\$) 0.00 | Claims Remaining After Amend.         | Highest No. Previously Paid For | Present Extra | Rate | Fee Paid                               | Total | -   | =   | x \$ 50.00 =                            |  | Indep. | -   | =  | x \$200.00 = |     |     |   |  | + \$360.00 = |     | TOTAL:   |  |     |     | (\$)  | SMALL ENTITY DISCOUNT: |     |    |                                   | (\$) | SUBTOTAL (2)              |  |  |  | (\$) 0.00                 | <div style="border-top: 1px solid black; padding-top: 5px;"> <table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:60%;"></td> <td style="width:40%; text-align: right;"> <b>SUBTOTAL (1)</b>      0.00<br/> <b>SUBTOTAL (2)</b>      0.00<br/> <b>SUBTOTAL (3)</b>      180.00               </td> </tr> </table> </div> <div style="border-top: 1px solid black; padding-top: 5px;"> <table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:60%; text-align: right;"><b>TOTAL</b></td> <td style="width:40%; text-align: right;">(\$)<b>180.00</b></td> </tr> </table> </div> |  | <b>SUBTOTAL (1)</b> 0.00<br><b>SUBTOTAL (2)</b> 0.00<br><b>SUBTOTAL (3)</b> 180.00 | <b>TOTAL</b> | (\$) <b>180.00</b> |
| Large Entity Fee (\$)  | Fee Description   | Fee Paid   |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 300  | Utility filing fee  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 500  | Utility search fee  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 200  | Utility exam fee  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 250  | Utility size fee (each add'l 50 pgs. over 100)  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 200  | Design filing fee   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 100  | Design search fee   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 130  | Design exam fee   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| 250  | Design size fee (each add'l 50 pgs. over 100)   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Number Filed   | Number Extra  | Rate   | Amount                |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Total Claims   | - 20 =  | x \$ 50.00 =   |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Independent Claims   | - 3 =   | x \$200.00 =   |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
|  |   |  | \$360.00 =            |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| TOTAL:   |   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| SMALL ENTITY DISCOUNT:   |   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| SUBTOTAL (1)   |   |  | (\$) 0.00             |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Claims Remaining After Amend.  | Highest No. Previously Paid For   | Present Extra  | Rate                  | Fee Paid        |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Total  | -   | =  | x \$ 50.00 =          |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Indep.   | -   | =  | x \$200.00 =          |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
|  |   |  | + \$360.00 =          |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| TOTAL:   |   |  |                       | (\$)            |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| SMALL ENTITY DISCOUNT:   |   |  |                       | (\$)            |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| SUBTOTAL (2)   |   |  |                       | (\$) 0.00       |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
|  | <b>SUBTOTAL (1)</b> 0.00<br><b>SUBTOTAL (2)</b> 0.00<br><b>SUBTOTAL (3)</b> 180.00  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| <b>TOTAL</b>   | (\$) <b>180.00</b>  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| <b>CORRESPONDENCE ADDRESS</b>  | <b>SIGNATURE BLOCK</b>  |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |
| Direct all correspondence to:<br>Patent Administrator<br>Goodwin Procter LLP<br>Exchange Place<br>Boston, MA 02109<br>Tel. No.: (617) 570-1000<br>Fax No.: (617) 523-1231<br>Customer No. 051414   | <div style="display: flex; justify-content: space-between;"> <div>           Date: March <u>24</u>, 2005<br/>           Reg. No.: 38,678<br/>           Tel. No.: (617) 570-1299<br/>           Fax No.: (617) 523-1231         </div> <div style="text-align: center;">           Respectfully submitted,<br/> <br/>           Duncan A. Greenhalgh<br/>           Attorney for the Applicants<br/>           Goodwin Procter LLP<br/>           Exchange Place<br/>           Boston, MA 02109         </div> </div>   |  |                       |                 |                    |     |     |                                     |  |     |                  |  |     |  |     |                           |                   |       |       |                                    |  |     |                 |  |     |   |     |   |              |      |        |  |        |              |     |   |       |              |      |  |  |     |            |                  |  |     |     |  |  |      |     |                          |  |     |           |                                       |                                 |               |      |  |       |     |     |   |  |        |     |  |              |     |     |   |  |              |     |  |  |     |     |   |                        |     |    |                                   |      |                           |  |  |  |                           |  |  |  |              |                    |



PATENT  
Attorney Docket No. MEE-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Miller *et al.*  
SERIAL NO.: 09/780,142 GROUP NO.: 1644  
FILING DATE: February 9, 2001 EXAMINER: Huynh, Phuong N.  
TITLE: METHODS AND COMPOSITIONS FOR TREATING CONDITIONS  
OF THE EYE

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

03/29/2005 LWONDIM1 00000022 09780142

01 FC:1806

180.00 DP

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

### STATEMENT


As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Date: March 24, 2005  
Reg. No. 38,678

Tel. No.: (617) 570-1299  
Fax No.: (617) 523-1231  
VER 11/03

Respectfully submitted,

  
\_\_\_\_\_  
Duncan A. Greenhalgh  
Attorney for Applicants  
Goodwin Procter LLP  
Exchange Place  
Boston, Massachusetts 02109  
Customer No. 051414





|   |  |  |           |                           |                                      |           |                            |               |                    |
|---|--|--|-----------|---------------------------|--------------------------------------|-----------|----------------------------|---------------|--------------------|
| FORM PTO - 1449                               |  |  |           |                           | ATTORNEY DOCKET NO.: MEE-002         |           |                            |               |                    |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |  |  |           |                           | APPLICANTS: Miller <i>et al.</i>     |           |                            |               |                    |
|   |  |  |           |                           | SERIAL NO.: 09/780,142               |           |                            |               |                    |
|   |  |  |           |                           | FILING DATE: February 9, 2001        |           |                            |               |                    |
|   |  |  |           |                           | EXAMINER: Huynh, P.      GROUP: 1644 |           |                            |               |                    |
| U.S. PATENT DOCUMENTS                         |  |  |           |                           |                                      |           |                            |               |                    |
| EXAM. INIT.                                   |  | DOCUMENT NUMBER  | DATE      | NAME                      | CLASS                                | SUB CLASS | FILING DATE IF APPROPRIATE |               |                    |
|   | A9   | 2002/0049247   | 4/25/2002 | Chen                      |                                      |           |                            |               |                    |
|   | A10  | 2003/0171320   | 9/11/2003 | Guyer <i>et al.</i>       |                                      |           |                            |               |                    |
|   | A11  | 2004/0167091   | 8/26/2004 | Guyer <i>et al.</i>       |                                      |           |                            |               |                    |
|   | A12  | 2005/0043220   | 2/24/2005 | Guyer <i>et al.</i>       |                                      |           |                            |               |                    |
|   | A13  | 6,270,749  | 8/7/2001  | Blumenkranz <i>et al.</i> |                                      |           |                            |               |                    |
| FOREIGN PATENT DOCUMENTS                      |  |  |           |                           |                                      |           |                            |               |                    |
| EXAM. INIT.                                   |  | DOCUMENT NUMBER  | DATE      | COUNTRY CODE              | CLASS                                | SUB CLASS | FILING DATE                | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|   | B8   | WO 97/05127  | 2/13/1997 |                           |                                      |           |                            |               |                    |
|   | B9   | WO 00/40089  | 7/13/2000 |                           |                                      |           |                            |               |                    |
|   | B10  | WO 01/58240  | 8/16/2001 |                           |                                      |           |                            |               |                    |
|   | B11  | WO 03/039404   | 5/15/2003 |                           |                                      |           |                            |               |                    |
| OTHER ART, JOURNAL ARTICLES, ETC.             |  |  |           |                           |                                      |           |                            |               |                    |
| EXAM. INIT.                                   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |           |                           |                                      |           |                            |               |                    |
|   | C119   | "A Clinical Trial to Evaluate the Effect of an Experimental Compound on Reducing the Number of Retreatments Required in Photodynamic Therapy (PDT) with Visudyne™," Alcon web site, <a href="http://www.alconlabs.com/us/co/c-00-07study.ihtml">http://www.alconlabs.com/us/co/c-00-07study.ihtml</a> (printed April 4, 2003). |           |                           |                                      |           |                            |               |                    |
|   | C120   | Adamis, "Looking Forward: Ocular Biochemical Warfare - The VEGF Attack," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).               |           |                           |                                      |           |                            |               |                    |
|   | C121   | Behling <i>et al.</i> , "Adeno-associated Delivery of TIMP-3 Inhibits Experimental Choroidal Neovascularization," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 1425 (2003).   |           |                           |                                      |           |                            |               |                    |
|   | C122   | Blumenkranz <i>et al.</i> , "Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5," <i>Arch Ophthalmol.</i> 120(10):1307-14 (Oct. 2002).  |           |                           |                                      |           |                            |               |                    |
|   | C123   | Bressler, "Photodynamic Therapy for AMD: Re-treatment Considerations," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).                 |           |                           |                                      |           |                            |               |                    |
|   | C124   | Campochiaro <i>et al.</i> , "The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration," <i>Molecular Vision</i> 5: 34-8 (Nov. 3, 1999).  |           |                           |                                      |           |                            |               |                    |
|   | C125   | Ciulla <i>et al.</i> , "Age-Related Macular Degeneration: A Review of Experimental Treatments," <i>Surv. Ophthalmol.</i> 43(2): 134-46 (1998).   |           |                           |                                      |           |                            |               |                    |
|   | C126   | Corjay <i>et al.</i> , "alpha <sub>v</sub> beta <sub>3</sub> , alpha <sub>v</sub> Beta <sub>5</sub> , and Osteopontin Immunostaining in Experimental Choroidal Neovascularization in the Monkey," Presentation #4473, Abstract on pg. S965.  |           |                           |                                      |           |                            |               |                    |
| EXAMINER                                      |  |  |           |                           | DATE CONSIDERED                      |           |                            |               |                    |

FORM PTO - 1449

ATTORNEY DOCKET NO.: MEE-002

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

APPLICANTS: Miller *et al.*

SERIAL NO.: 09/780,142

FILING DATE: February 9, 2001

EXAMINER: Huynh, P. GROUP: 1644

OTHER ART, JOURNAL ARTICLES, ETC.

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |
|----------------|--|--|
|                | C127   | Csaky, K., "Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls (Comment)," <u>Ophthalmology</u> 110(5):879-81 (May 2003).   |
|                | C128   | Dahlin <i>et al.</i> , "Design of a Specialized Cannula for Poseterior Juxtapapillary Delivery of Anecortave Acetate to the Retina for Treatment CNV Associated with Age-Related Macular Degeneration," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 5036 (2003).   |
|                | C129   | Danis, "Pharmacotherapy for AMD: The Role of Intravitreal Steroids and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).                |
|                | C130   | de Juan, "Surgery for AMD: Limited Translocation in the Era of Photodynamic Therapy," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).                  |
|                | C131   | Eyetechnology Study Group, "Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results," <u>Ophthalmology</u> 110(5):979-86 (May 2003).  |
|                | C132   | Gallemler <i>et al.</i> , "AMD Treatment Update: Along with Visudyne and TTT, injectable anti-angiogenesis agents are on the forefront of current research," <u>Ophthalmology Management</u> , 69-72 (March 2003).   |
|                | C133   | Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab V2, an Anti-vascular Endothelial Growth Factor (VEGF) in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO Poster</u> .  |
|                | C134   | Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," <u>ARVO. The Association for Research in Vision and Ophthalmology</u> (Oasis, Online Abstract Submission and Invention System, Program Planner, Presentation # 566). |
|                | C135   | Granville <i>et al.</i> , "Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells," <u>International Immunopharmacology</u> 1: 1831-40 (2001).  |
|                | C136   | Guyer, D.R., "Pharmacotherapy for AMD: VEGF Inhibitors and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).                            |
|                | C137   | Haimovici <i>et al.</i> , "Localization of Lipoprotein-delivered benzoporphyrin derivative in the rabbit eye," <u>Curr. Eye Res.</u> 16(2):83-90 (1997).   |
|                | C138   | Heier <i>et al.</i> , "rhuFAB V2 (an Anti-VEGF Antibody Fragment) in Neovascular AMD: Safety and Tolerability of Multiple Intravitreal Injections - Preliminary Data from a Single Center," <u>ARVO Poster</u> .   |
|                | C139   | Husain <i>et al.</i> , "Effects of Photodynamic Therapy Using Verteporfin on Experimental Choroidal Neovascularization and Normal Retina and Choroid up to 7 Weeks after Treatment," <u>Invest. Ophthalmol Vis Sci.</u> 40(10): 2322-31 (1999).  |
|                | C140   | Husain <i>et al.</i> , "Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative," <u>Ophthalmology</u> 104(8):1242-50 (Aug. 1997).  |
|                | C141   | International Search Report for PCT/US01/04231 completed on November 23, 2001  |
|                | C142   | Kaiser <i>et al.</i> , "Five-Year Results of Verteporfin Therapy for Subfoveal CNV Due to AMD: Third Year of an Open-label Extension of the TAP Investigation," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 1099 (2003).   |
|                | C143   | Kitchen <i>et al.</i> , "Anecortave Acetate Monotherapy for the Treatment of Occult and Minimally Classic Choroidal Neovascularization in Age-related Macular Degeneration," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 5039 (2003).  |
| EXAMINER       |  | DATE CONSIDERED  |

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

US 09/780,142

Sheet 3 of 4


|   |  |  |
|---|--|--|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT<br>PTO - 1449 |  | ATTORNEY DOCKET NO.: MEE-002<br><br>APPLICANTS: Miller <i>et al.</i><br><br>SERIAL NO.: 09/780,142<br><br>FILING DATE: February 9, 2001<br><br>EXAMINER: Huynh, P.      GROUP: 1644  |
| OTHER ART, JOURNAL ARTICLES, ETC.                           |  |  |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |
|   | C144   | Kliman <i>et al.</i> , "Angiography and Photodynamic Therapy of Experimental Choroidal Neovascularization using Phthalocyanine Dye," <i>Invest. Ophthalmol. Vis. Sci. (Suppl.)</i> 30(3): 371 (1989).  |
|   | C145   | Krzystolik <i>et al.</i> , "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment," <i>Arch. Ophthalmol.</i> 120(2): 338-346 (2002).   |
|   | C146   | Lai <i>et al.</i> , "Suppression of Choroidal Neovascularization by Adeno-associated Virus Vector Expressing Angiostatin," <i>Investigative Ophthalmology &amp; Visual Science</i> 42 (10): 2401-2407 (2001).  |
|   | C147   | Leibowitz <i>et al.</i> , "The Framingham Eye Study Monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults," <i>Survey of Ophthalmology, Supplement</i> (May-June 1980).                   |
|   | C148   | Miller, "Photodynamic Therapy for AMD: Expanded Indications," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).                    |
|   | C149   | Ngo <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and Levinthal Paradox," Chapter 14 of <i>The Protein Folding and Tertiary Structure Prediction</i> , Merz and LeGrand, Eds., Burkhauser Boston, 1994.   |
|   | C150   | Oleinick <i>et al.</i> , "The role of apoptosis in response to photodynamic therapy: what, where, why, and how," <i>Photochem. Photobiol. Sci.</i> 1: 1-21 (2002).   |
|   | C151   | Olsen <i>et al.</i> , "An Evaluation of an Episcleral Anecortave Acetate Transscleral Drug Delivery System in Rhesus Monkey," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 4213 (2003).   |
|   | C152   | Pasqualini <i>et al.</i> , "Organ Targeting in Vivo using Phage display Peptide Libraries," <i>Nature</i> 380: 364-6 (1996).   |
|   | C153   | Reinke <i>et al.</i> , "Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey," <i>Ophthalmology</i> 106(10):1915-23 (Oct. 1999).   |
|   | C154   | Renno <i>et al.</i> , "Expression of pigment epithelium-derived factor in experimental choroidal neovascularization," <i>Invest Ophthalmol Vis Sci.</i> 43(5):1574-80 (May 2002).  |
|   | C155   | Renno <i>et al.</i> , "Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells," <i>Invest Ophthalmol Vis Sci.</i> 41(12):3963-71 (Nov 2000).  |
|   | C156   | Renno <i>et al.</i> , "Photosensitizer delivery for photodynamic therapy of choroidal neovascularization," <i>Adv Drug Deliv Rev.</i> 52(1):63-78 (Oct. 31, 2001) Review.  |
|   | C157   | Renno <i>et al.</i> , "Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2," <i>Arch Ophthalmol.</i> 122(7):1002-11 (July 2004).  |
|   | C158   | Schlingemann <i>et al.</i> , "Role of vascular permeability factor/vascular endothelial growth factor in eye disease," <i>Br. J. Ophthalmol.</i> 81: 501-12 (1997)   |
|   | C159   | Schmidt-Erfurth <i>et al.</i> , "Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study," <i>Arch Ophthalmol.</i> 117(9):1177-87 (Sept. 1999). Erratum in: <i>Arch Ophthalmol.</i> 118(4):488 (April 2000). |
|   | C160   | Sickenberg <i>et al.</i> , "A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes," <i>Arch Ophthalmol.</i> 118(3):327-36 (March 2000).  |
|   | C161   | Slakter <i>et al.</i> , "Ancortave Acetate Administered as a Posterior Juxtapapillary Injection for Subfoveal CNV in Age-Related Macular Degeneration (AMD-Clinical Results)," Presentation at the Retina Congress 2002 Symposium (Sept. 8, 2002).   |
| EXAMINER  |  | DATE CONSIDERED  |



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

US 09/780,142

Sheet 4 of 4

|   |  |  |  |
|---|--|--|--|
|  RECEIVED PTO - 1449<br>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |  | ATTORNEY DOCKET NO.: MEE-002<br><br>APPLICANTS: Miller <i>et al.</i><br><br>SERIAL NO.: 09/780,142<br><br>FILING DATE: February 9, 2001<br><br>EXAMINER: Huynh, P.      GROUP: 1644  |  |
| OTHER ART, JOURNAL ARTICLES, ETC.   |  |  |  |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |  |
|   | C162   | Slakter, "Pharmacotherapy for AMD: The Role of Periocular Steroids and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).      |  |
|   | C163   | Slakter <i>et al.</i> , "Sub-Tenon's Administration of the Angiostatic Agent Anecortave Acetate in AMD Patients with Subfoveal Choroidal Neovascularization (CNV) - the Clinical Outcome," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 2909 (2002).  |  |
|   | C164   | Slakter <i>et al.</i> , "Verteporfin With Altered (Delayed) Light in Occult CNV (VALIO) - Results of a Phase II Controlled Clinical Trial," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 1101 (2003).   |  |
|   | C165   | Trese, "Treatment of Neovascularization in ROP: Pharmacological Agents and the ERTOP Study," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002). |  |
|   | C166   | Verma <i>et al.</i> , "Gene therapy - Promises, problems and prospects," <i>Nature</i> 389: 239-42 (Sept. 1997).   |  |
|   | C167   | Yaacobi <i>et al.</i> , "In-Vivo Studies with Trans-Scleral Anecortave Acetate Delivery Device Designed to Treat Choroidal Neovascularization in AMD," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 4210 (2003).  |  |
|   | C168   | Zacks <i>et al.</i> , "Caspase Activation in an Experimental Model of Retinal Detachment," <i>Investigative Ophthalmology &amp; Visual Science</i> 44(3): 1262-7 (March 2002).   |  |
|   | C169   | Zacks <i>et al.</i> , "Verteporfin Photodynamic Therapy in the Rat Model of Choroidal Neovascularization: Angiographic and Histologic Characterization," <i>Investigative Ophthalmology &amp; Visual Science</i> 43 (0): 1-9 (2002).   |  |
| EXAMINER  |  | DATE CONSIDERED  |  |